Cantor Fitzgerald Downgrades Seattle Genetics (SGEN) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Wall Street sinks as bond yields rise, Walmart results disappoint
Seattle Genetics Reports Second Quarter 2016 Financial Results
July 26, 2016 4:02 PM EDT-Second Quarter 2016 Revenues Were $95.4 Million, Including Record $66.2 Million in ADCETRIS® (Brentuximab Vedotin) U.S. and Canada Net Sales-
-Top-Line Data from ADCETRIS Phase 3 ALCANZA Trial Expected in Third Quarter of 2016-
-Conference Call Today at 4:30 p.m. ET-
BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (NASDAQ: SGEN) today reported financial results for... More
